Showing results (91-100 of 193) with videos related to
Sort By:
Pageof 20
Chemmedchem|March 26, 2024
Uracil- and Pyridine-Containing HDAC Inhibitors Displayed Cytotoxicity in Colorectal and Glioblastoma Cancer Stem CellsFrancesco Fiorentino, Emanuele Fabbrizi, Alessia Raucci, et al.Clinical Epigenetics|April 11, 2018
KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2Elisa Cocco, Manuela Leo, Claudia Canzonetta, et al.Pharmaceutics|June 27, 2025
Optimization of Lipoplexes Functionalized with a Sialic Acid Mimetic (F9-PEG) to Target the C1858T PTPN22 Variant for Preclinical Assessment of a Novel Immunotherapy in Endocrine AutoimmunitySimona Sennato, Giorgia Paldino, Cecilia Bombelli, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|June 7, 2019
Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysisVeronica Di Paolo, Chiara Fulci, Dante Rotili, et al.Oncotarget|January 18, 2015
A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenograftsAnastasia De Luca, Dante Rotili, Debora Carpanese, et al.Journal of Medicinal Chemistry|September 10, 2019
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from Schistosoma mansoni (SmSirt2)Daria Monaldi, Dante Rotili, Julien Lancelot, et al.Pharmaceuticals (Basel, Switzerland)|January 28, 2026
A Combined SIRT5 Activation and SIRT3 Inhibition Prevents Breast Cancer Spheroids Growth by Reducing HIF-1α and MitophagyFederica Barreca, Michele Aventaggiato, Mario Cristina, et al.ACS Medicinal Chemistry Letters|May 22, 2020
From PARP1 to TNKS2 Inhibition: A Structure-Based ApproachStefano Tomassi, Julian Pfahler, Nicola Mautone, et al.Journal of Medicinal Chemistry|July 16, 2011
Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitorsGianluca Sbardella, Antonello Mai, Sara Bartolini, et al.EMBO Reports|June 6, 2009
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexesAngela Nebbioso, Fabio Manzo, Marco Miceli, et al.Pageof 20